Free Trial
NASDAQ:ACRV

Acrivon Therapeutics Q4 2024 Earnings Report

Acrivon Therapeutics logo
$1.23 -0.10 (-7.52%)
Closing price 04:00 PM Eastern
Extended Trading
$1.22 -0.01 (-0.81%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Acrivon Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acrivon Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 26, 2025
Conference Call Time
7:00PM ET

Upcoming Earnings

Acrivon Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Friday, May 9, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Acrivon Therapeutics Earnings Headlines

FY2025 EPS Estimates for ACRV Boosted by Cantor Fitzgerald
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
See More Acrivon Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acrivon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acrivon Therapeutics and other key companies, straight to your email.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV), a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

View Acrivon Therapeutics Profile

More Earnings Resources from MarketBeat